Physician profile
Blayne Knapp
NPI 1427678986
$2,187.36
in general payments reported to CMS, 2019-2025
14 companies · $620 in 2025
The $620 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $152 · 2023: $395 · 2024: $893 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.62 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $393.91 | 2023-2025 | Kcentra, Hizentra |
| Genzyme Corporation | $366.27 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.98 | 2023-2025 | Ofev |
| Shionogi INC | $249.98 | 2024-2025 | Fetroja |
| Boston Scientific Corporation | $138.10 | 2023 | Watchman Access System |
| Amgen INC. | $125.00 | 2025 | Tavneos |
| Actelion Pharmaceuticals US, INC. | $122.88 | 2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $113.68 | 2024 | Dupixent |
| Grifols USA, LLC | $109.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $108.80 | 2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $100.93 | 2021 | |
| Glaxosmithkline, LLC. | $42.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.90 | 2024 | Xarelto |
| Abbvie INC. | $26.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blayne Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.